CORE-VNS real-world evidence demonstrates 80% median seizure reduction in drug-resistant epilepsy

LivaNova/VNS Therapy System

Long-term real-world evidence from the CORE-VNS study, the largest dataset of VNS Therapy outcomes, showed a median seizure reduction of 80% in patients with focal onset seizures with impaired awareness and 95% in those with focal-to-bilateral tonic-clonic seizures, supporting VNS as a durable therapy for drug-resistant epilepsy.